Outcomes of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for 10 patients with myelofibrosis.
10.3760/cma.j.issn.0253-2727.2018.03.010
- VernacularTitle:减低强度预处理异基因造血干细胞移植治疗10例骨髓纤维化患者的临床观察
- Author:
Hui Xia LIU
1
;
Jun YANG
;
Jie Ling JIANG
;
Yu CAI
;
Li Ping WAN
;
Lin WU
;
Shan SHAO
;
Chun WANG
Author Information
1. Department of Hematology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China.
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Myelofibrosis;
Transplantation conditioning
- MeSH:
Adult;
Busulfan;
Female;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Middle Aged;
Primary Myelofibrosis;
Prospective Studies;
Transplantation Conditioning;
Vidarabine;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(3):225-230
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo-HSCT) for patients with myelofibrosis (MF). Methods: The clinical data of 10 patients with myelofibrosis (MF) who underwent RIC-allo-HSCT. Results: Of all 10 patients, 6 were male and 4 women, with a median age of 28.5 (22-54). Using fludarabine/busulfan plus total body irradiation (FB+TBI) pretreatment scheme based. Hematopoiesis reconstitution was achieved in 9 patients (90%). The median time of neutrophil and platelet engraftment was 13.5 (10-22) day and 16.5 (13-40) day, respectively. Acute GVHD occurred in 4 cases while chronic GVHD in 5 cases. The prospective OS for 3 years was (90.0±8.5)% after a median follow-up time of 17 months. Transplant related mortality was 1 case. Conclusion: RIC-HSCT with FB+TBI is a feasible and effective alternative for MF patients.
